Format

Send to

Choose Destination
Prog Urol. 2018 Jan;28(1):18-24. doi: 10.1016/j.purol.2017.10.001. Epub 2017 Dec 6.

Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?

Author information

1
Department of urology, institut Jules-Bordet, université libre de Bruxelles (ULB), Brussels, Belgium; Department of urology, cliniques universitaires de Bruxelles, hôpital Erasme, ULB, Brussels, Belgium. Electronic address: Simone.albisinni@erasme.ulb.ac.be.
2
Department of urology, institut Jules-Bordet, université libre de Bruxelles (ULB), Brussels, Belgium; Department of urology, Hôtel-Dieu de France, Beirut, Lebanon.
3
Department of urology, institut Jules-Bordet, université libre de Bruxelles (ULB), Brussels, Belgium.
4
Department of oncology, Hôtel-Dieu de France, Beirut, Lebanon.
5
Department of radiology, institut Jules-Bordet, ULB, Brussels, Belgium.
6
Department of statistics, institut Jules-Bordet, ULB, Brussels, Belgium.
7
Department of urology, institut Jules-Bordet, université libre de Bruxelles (ULB), Brussels, Belgium; Department of urology, cliniques universitaires de Bruxelles, hôpital Erasme, ULB, Brussels, Belgium.

Abstract

INTRODUCTION AND OBJECTIVES:

MRI-guided targeted biopsies are advised in patients who have undergone an initial series of negative systematic biopsies, in whom prostate cancer (PCa) suspicion remains elevated. The aim of the study was to evaluate whether, in men with prior negative prostate biopsies, systematic cores are also warranted at the time of an MRI-targeted repeat biopsy.

MATERIAL AND METHODS:

We enrolled patients with prior negative biopsy undergoing real time MRI/TRUS fusion guided prostate biopsy at our institute between 2014 and 2016. Patients with at least one index lesion on multiparametric MRI were included. All eligible patients underwent both systematic random biopsies (12-14 cores) and targeted biopsies (2-4 cores).

RESULTS:

The study included 74 men with a median age of 65 years, PSA level of 9.27ng/mL, and prostatic volume of 45ml. The overall PCa detection rate and the clinically significant cancer detection rate were 56.7% and 39.2%, respectively. Targeted cores demonstrated similar clinically significant PCa detection rate compared to systematic cores (33.8% vs. 28.4%, P=0.38) with significantly less tissue sampling. Indeed, a combination approach was significantly superior to a targeted-only in overall PCa detection (+16.7% overall detection rate, P=0.007). Although differences in clinically significant PCa detection were statistically non-significant (P=0.13), a combination approach did allow detecting 7 extra clinically significant PCas (+13.8%).

CONCLUSIONS:

In patients with elevated PSA and prior negative biopsies, concurrent systematic sampling may be needed at the time of targeted biopsy in order to maximize PCa detection rate. Larger studies are needed to validate our findings.

LEVEL OF EVIDENCE:

4.

KEYWORDS:

Biopsies ciblées de prostate; Cancer de prostate; Cancer detection; Diagnostic; Fusion RMN/échographie; MRI/US fusion; Prostate cancer; Targeted prostate biopsies

PMID:
29203158
DOI:
10.1016/j.purol.2017.10.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center